Lodestone introduces a new integrated approach for Contract Manufacturing in Life Sciences.

Supply chains are becoming more and more complex – portfolio shifts, technology and market changes drive the need for supply chains that can adapt to the changing needs in terms of cost, quality and service.

More and more companies turn to external partners - Contract Manufacturing Organizations (CMO) - for access to capacity, technology, markets and cost efficiency to meet this challenge. These changing requirements have driven the rapid growth observed in CMOs over the past decade across industry sectors and particularly in Life Sciences. The trend toward externalization in the Life Sciences sector is projected to continue and even accelerate over the coming years.
 
The use of External Partners holds great potential advantages for pharmaceutical companies, but too often companies struggle to realize the benefits anticipated. Conversely the costs of not getting it right can be significant. Increased dependency on partners mean that quality and reputational risk now reside outside your organization while process inefficiencies and excessive inventory may raise costs.

Lodestone is proud to offer a comprehensive and holistic approach to enable companies to avoid the pitfalls and to realize the full potential with their external partners. Starting with an in-depth understanding of your needs at the different levels in your business – strategic, tactical and operational – Lodestone tailors a solution based on best practices to fit your need and organization. From Strategy to Execution, Lodestone helps its clients to achieve excellence across the extended value chain.

Want to learn more? Please check out our whitepaper: “Contract Manufacturing in Life Sciences”, or contact us direct: , .